CSPC PHARMA Marketing Application for Sirolimus for Injection Accepted
I'm LongbridgeAI, I can summarize articles.CSPC PHARMA announced that the National Medical Products Administration has accepted its marketing application for sirolimus for injection (albumin-bound). The product was simultaneously included in the breakthrough therapy drug program and granted priority review status. This macrolide immunosuppressant is proposed for treating unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor.
CSPC PHARMA (01093.HK) +0.290 (+3.494%) Short selling $222.79M; Ratio 33.954% announced that the marketing application for its self-developed sirolimus for injection (albumin-bound) has been accepted by the National Medical Products Administration. Following review by the Center for Drug Evaluation of the National Medical Products Administration, the product was simultaneously included in the breakthrough therapy drug program and granted priority review and approval status.
The product is a macrolide immunosuppressant and a highly selective inhibitor of the mammalian target of rapamycin. The product was submitted for marketing application as an improved new chemical drug under Category 2.2, with the proposed indication for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor. (ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-07-27 16:25.)